Precision BioSciences (DTIL) Competitors $4.54 +0.01 (+0.22%) Closing price 04:00 PM EasternExtended Trading$4.84 +0.31 (+6.72%) As of 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DTIL vs. LYEL, SCPH, IVA, CCCC, CGEN, EPRX, ACTU, ARTV, TIL, and PRQRShould you be buying Precision BioSciences stock or one of its competitors? The main competitors of Precision BioSciences include Lyell Immunopharma (LYEL), scPharmaceuticals (SCPH), Inventiva (IVA), C4 Therapeutics (CCCC), Compugen (CGEN), Eupraxia Pharmaceuticals (EPRX), Actuate Therapeutics (ACTU), Artiva Biotherapeutics (ARTV), Instil Bio (TIL), and ProQR Therapeutics (PRQR). These companies are all part of the "pharmaceutical products" industry. Precision BioSciences vs. Lyell Immunopharma scPharmaceuticals Inventiva C4 Therapeutics Compugen Eupraxia Pharmaceuticals Actuate Therapeutics Artiva Biotherapeutics Instil Bio ProQR Therapeutics Lyell Immunopharma (NASDAQ:LYEL) and Precision BioSciences (NASDAQ:DTIL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, community ranking, profitability, dividends, analyst recommendations, institutional ownership and media sentiment. Does the MarketBeat Community believe in LYEL or DTIL? Precision BioSciences received 80 more outperform votes than Lyell Immunopharma when rated by MarketBeat users. Likewise, 68.61% of users gave Precision BioSciences an outperform vote while only 46.67% of users gave Lyell Immunopharma an outperform vote. CompanyUnderperformOutperformLyell ImmunopharmaOutperform Votes1446.67% Underperform Votes1653.33% Precision BioSciencesOutperform Votes9468.61% Underperform Votes4331.39% Does the media refer more to LYEL or DTIL? In the previous week, Precision BioSciences had 6 more articles in the media than Lyell Immunopharma. MarketBeat recorded 10 mentions for Precision BioSciences and 4 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 1.20 beat Precision BioSciences' score of -0.19 indicating that Lyell Immunopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lyell Immunopharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Precision BioSciences 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate LYEL or DTIL? Lyell Immunopharma currently has a consensus price target of $1.00, suggesting a potential upside of 68.46%. Precision BioSciences has a consensus price target of $37.67, suggesting a potential upside of 729.66%. Given Precision BioSciences' stronger consensus rating and higher possible upside, analysts clearly believe Precision BioSciences is more favorable than Lyell Immunopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyell Immunopharma 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Precision BioSciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, LYEL or DTIL? Lyell Immunopharma has a beta of -0.41, indicating that its stock price is 141% less volatile than the S&P 500. Comparatively, Precision BioSciences has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500. Do insiders & institutionals believe in LYEL or DTIL? 66.1% of Lyell Immunopharma shares are owned by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are owned by institutional investors. 25.1% of Lyell Immunopharma shares are owned by company insiders. Comparatively, 4.0% of Precision BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is LYEL or DTIL more profitable? Precision BioSciences has a net margin of 11.48% compared to Lyell Immunopharma's net margin of -323,792.09%. Precision BioSciences' return on equity of -23.69% beat Lyell Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets Lyell Immunopharma-323,792.09% -34.64% -30.02% Precision BioSciences 11.48%-23.69%-6.98% Which has stronger earnings & valuation, LYEL or DTIL? Precision BioSciences has higher revenue and earnings than Lyell Immunopharma. Lyell Immunopharma is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLyell Immunopharma$61K2,872.92-$234.63M-$1.31-0.45Precision BioSciences$75.10M0.46-$61.32M$0.0675.67 SummaryPrecision BioSciences beats Lyell Immunopharma on 14 of the 18 factors compared between the two stocks. Remove Ads Get Precision BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DTIL vs. The Competition Export to ExcelMetricPrecision BioSciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.83M$3.04B$5.64B$8.06BDividend YieldN/A1.54%4.57%4.02%P/E Ratio75.6829.2923.1319.03Price / Sales0.46436.17383.8993.17Price / CashN/A168.6838.1634.64Price / Book1.003.956.944.33Net Income-$61.32M-$71.95M$3.20B$247.06M7 Day Performance-15.30%-4.63%-2.30%-0.52%1 Month Performance-17.30%-9.29%3.10%-3.73%1 Year Performance-65.02%-25.75%11.22%1.74% Precision BioSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DTILPrecision BioSciences4.2297 of 5 stars$4.54+0.2%$37.67+729.7%-64.5%$34.83M$75.10M75.68200Short Interest ↓News CoverageGap UpLYELLyell Immunopharma3.7368 of 5 stars$0.52-11.7%$1.00+93.4%-71.2%$152.66M$61,000.00-0.65270Insider TradeShort Interest ↓Positive NewsSCPHscPharmaceuticals3.7648 of 5 stars$3.00-1.0%$15.00+400.0%-38.7%$150.12M$30.28M-1.5830IVAInventiva2.2292 of 5 stars$2.85-4.4%$12.60+342.1%-23.4%$149.56M$15.62M0.00100News CoverageCCCCC4 Therapeutics2.6086 of 5 stars$2.09+3.0%$12.50+498.1%-76.7%$148.37M$35.58M-1.23150CGENCompugen2.0485 of 5 stars$1.63-1.2%$4.00+145.4%-38.8%$145.46M$27.86M81.5070Positive NewsEPRXEupraxia Pharmaceuticals2.3272 of 5 stars$4.08-1.7%$10.50+157.4%N/A$145.40MN/A-5.6729Earnings ReportGap DownACTUActuate TherapeuticsN/A$7.40+2.1%$20.00+170.3%N/A$144.54MN/A0.0010Gap DownARTVArtiva BiotherapeuticsN/A$5.87+15.1%$21.00+257.8%N/A$142.58M$2.60M0.0081Analyst ForecastAnalyst RevisionNews CoverageTILInstil Bio3.226 of 5 stars$21.63+8.8%$114.00+427.0%+63.4%$141.16MN/A-1.87410Positive NewsPRQRProQR Therapeutics2.0181 of 5 stars$1.70+0.6%$9.50+458.8%-36.7%$138.86M$18.91M-5.31180Analyst RevisionPositive News Remove Ads Related Companies and Tools Related Companies Lyell Immunopharma Alternatives scPharmaceuticals Alternatives Inventiva Alternatives C4 Therapeutics Alternatives Compugen Alternatives Eupraxia Pharmaceuticals Alternatives Actuate Therapeutics Alternatives Artiva Biotherapeutics Alternatives Instil Bio Alternatives ProQR Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DTIL) was last updated on 3/27/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precision BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precision BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
